Home » Case Studies » Value Access and Pricing » PCSK9 Indication Expansion P&#…

PCSK9 Indication Expansion P&MA and Commercial Assessment

CBPartners completed an EU indication expansion P&MA and Commercial assessment for a PCSK9 product across the EU4 and the Netherlands.


To understand the pricing and access potential as well as utilization impact of PRODUCT X’s launch in the […] indication and to inform PRODUCT X forecast assumptions and life-cycle management (LCM) and evidence generation strategy in the EU.



Conduct qualitative research with n=11 payers, n=4 key opinion leaders (KOLs), and n=25 community physicians to understand the impact the indication expansion on market specific access restrictions and high-level impact on the treatment selection framework. Execute quantitative research with n=318 community physicians to quantify impact on utilization in the context of pricing and market access (P&MA).


  • Impact of indication expansion on pricing and market access.
  • Impact on treatment selection within indication.
  • Physician halo impact on primary indications.
  • LCM utilization forecast assumptions.
  • Trial refinement feedback based on payer / physician insights.

Illustrative outputs


CBP provided a seamless EU P&MA and utilization assessment within a three-month timeline.